Craniofacial development requires orchestrated and complex interactions between multiple tissues of different origins. Cranial neural crest stem cells migrate from the dorsal neural tube into the frontonasal process and branchial arches where they ultimately form most of the skeletal structures and connective tissue of the craniofacial complex, as well as contributing neurons and glia to cranial ganglia. The timing and mechanism by which cranial neural crest cells progressively differentiate from multipotent stem cells into lineage restricted and terminally differentiating cell types has previously not been investigated. In addition, there are many deficits in our knowledge of the molecular controls regulating early development of neural crest cells within the branchial arches. Spatial and temporal changes in migratory and lineage potential in neural crest populations contributing to the developing first branchial arch and trigeminal ganglia were examined by back-transplanting cells from quail into chick embryos. Neural crest cells that had barely entered the first branchial arch had largely lost both the ability to localise to the trigeminal ganglia and neurogenic differentiation capacity but were still capable of long-distance migration. However, after a further 12 hours residence in the branchial arch, neural crest cells had lost long-distance migratory ability.

PhD, Faculty of Health Sciences, University of the Witwatersrand / While ethanol is recognised beyond doubt as a teratogen to the unborn fetus, research nevertheless continues in order to understand its mode of action and its effects at the cellular level. The present study aimed to investigate the effect of an acute dose of ethanol on cranial morphology and morphometry in mouse fetuses, as well as on the morphology, migration and the expression of cell migration related genes in cultured chick cranial neural crest cells (cNCCs). Thirteen pregnant C57/BL mice were orally administered with 0.03ml/g of 25% (v/v) ethanol daily on gestational days (GD) 6, 7 and 8. Ten control animals received an identical dose of saline. On GD 18, all mice dams were killed and their fetuses were removed. Fetal morphological observations and crown-rump lengths were evaluated as were mean litter size, survival rate, birth weight and cranial dimensions. Cranial neural crest cells (cNCCs) were cultured from Potchefstroom koek koek stages 8-10 (HH) chick embryo neural tubes either in culture medium (DMEM) to which 0.2%, 0.3% and 0.4% ethanol (v/v) respectively, was added (treated) or in DMEM only (controls). Whole-mount HNK-1 immunocytochemistry was performed on treated and control chick embryos, as was an assay for caspase-dependent apoptosis. Photographs were taken of the cultures and the distance which the neural crest cells migrated from the neural tube at 24 and 48 hrs post-culture was measured. 24-hr time-lapse video microscopy recordings were also made to analyse the migration of the neural crest cells. Rhodamine-phalloidin immunocytochemistry for the actin cytoskeleton and scanning electron microscopy of surface ultrastructure were performed on migrating treated and non-treated cNCCs, as were proliferation assays and quantitative PCR of cNCCs‟ β-actin, Rac 1, Rho B and slug genes. There was a statistically significant increase in fetal reabsorption as well as a significantly reduced fetal survival rate observed in newborn mice fetuses that had been exposed to ethanol in utero compared to control fetuses. Ethanol-exposed mice showed a number of abnormalities, which were not significantly increased over vi controls (p>0.5). Birth weight, crown-rump length and mandibular length were also not significantly different in treated fetuses compared to controls (p>0.5). Treated (0.3%) chick cNCCs migrated over a significantly increased distance at both 24hrs and 48hrs compared to controls (p<0.05) in the axes of migration that were studied. The migratory distances of cNCCs derived from embryonic stage 9 (HH) were markedly affected by treatment with alcohol. The actin cytoskeleton of treated cNCCs showed disorganisation and loss of focal adhesion contacts while Rac 1, Rho B and slug genes were either up-regulated or down-regulated depending on the ethanol dose and duration of treatment. Ethanol promotes significant proliferation in cNCCs and may affect their migration by altering the expression of migration-linked genes and the arrangement of the actin cytoskeleton.

In this thesis, several techniques were combined to optimize, evaluate and characterize craniofacial development in Xenopus, with additional focus on understanding the alterations made during maturation in the craniofacial region and the cartilage. Three important techniques used were: confocal microscopy in conjunction with Acridine Orange (AO) labeling, Alcian Blue (AB) labeling, and geometric morphometric analysis. I found that facial width increased across all techniques used to evaluate it. Included within this focus was the study of the development of the ceratohyal (CH) cartilage, which supported the mouth and snout. This was also found to increase width wise, in unison with facial and orofacial growth. This data may suggest a link between the face, mouth and CH growth, in which the developing cartilage elongates and widens causing the increase seen in the width and distension of the mouth.

The hedgehog morphogenic pathway is essential for the development of numerous organs and tissues in both vertebrates and invertebrates, and dysregulation of hedgehog signalling is also associated with a broad range of mammalian cancers. While a great deal of research has been dedicated to understanding the molecular interactions of the hedgehog signalling pathway itself, much work remains in understanding the downstream transcriptional output of the pathway, and how that output modulates cellular behaviour in target tissues to produce developmental outcomes. The hedgehog pathway is activated by hedgehog proteins and repressed by patched. Downstream of these regulators, the hedgehog signalling cascade involves modification and trafficking of a series of key proteins and ultimately leads to regulation of the GLI family of transcription factors, thereby modulating the transcriptional output of the pathway. This thesis builds on previous work investigating downstream targets of one GLI protein – GLI3 – in the mouse limb (McGlinn et al., 2005). This previous study identified genes that were dysregulated in the anterior limb of the Gli3-null, extra-toes strain of mice (Gli3Xt/Xt). Amongst the identified targets of GLI3 were a number of novel genes. However, further detailed analysis of these genes was not conducted, and therefore, this thesis investigates the embryonic expression or function of three of these novel downstream targets of GLI3, to clarify their regulation by the hedgehog pathway and identify their broader role throughout development. One published work and one paper submitted for publication are contained within this thesis, describing detailed expression of two novel SHH targets, Zinc finger protein 503 (Zfp503) and Pitrolysin metallopeptidase 1 (Pitrm1). Zfp503 belongs to a family of transcription factors that regulate aspects of development across a diversity of species. However, their role in mammals and avians has been poorly described. This manuscript presents a detailed description of Zfp503 expression in the mouse and chicken and examines regulation of Zfp503 in the limb by SHH and BMP signalling. My contribution to this paper was the analysis of WT Zfp503 expression in mouse and chick by section in situ hybridisation, and as such, I am listed as a middle author. Pitrm1 is a metallopeptidase with a broad range of predicted target molecules. Comparisons with family members in mammals and plants suggest Pitrm1 has mitochondrial function and is implicated in the pathology of Alzheimers disease. It is upregulated in response to hedgehog pathway activation in the anterior limb of two mouse models of hedgehog signalling– the Gli3Xt/Xt and Ptch1:Prx-Cre mouse line, which deletes patched1 in the developing limb. It is expressed in multiple developing tissues that are patterned by SHH, suggesting that Pitrm1 may be an important regulator of developmental processes downstream of SHH. For the Pitrm1 manuscript, I contributed the majority of the experimental data and prepared the manuscript, and therefore, I am the first listed author. A third downstream hedgehog target gene described in this thesis is Tmem26. Tmem26 is an entirely novel gene with unknown cellular function, although concurrent work in the Wicking laboratory suggests that Tmem26 regulates cell migration and morphology in cell culture. Tmem26 is negatively regulated by SHH in the anterior mouse limb at 11.5dpc, as shown by use of Gli3Xt/Xt and Ptch1:Prx-Cre mice. Tmem26 expression in wild-type mice is spatially restricted and strikingly evident in the facial prominences, particularly near the point of fusion of the developing lip and in the shelves of the secondary palate. This suggests that Tmem26 may be involved in lip and palate formation and possibly play a role in the common human birth disorders of cleft lip and cleft palate. Generation of a Tmem26 conditional knockout mouse line, followed by germline inactivation of Tmem26 using a ubiquitously expressed Cre line, did not reveal a craniofacial phenotype in embryos or adults. Knockout mice appear healthy and fertile with no obvious developmental defects. This does not preclude a role for Tmem26 in facial development however, as molecular redundancy may be able to compensate for Tmem26 loss in mice. Tmem26 is also expressed in cells and organs of the adult immune system and suggests an alternative possible role for Tmem26 in regulating immune function that could be further investigated using the Tmem26 conditional knockout mouse line.

Objective: To follow a cohort of children from age 4-6-12 with respect to sleep disordered breathing (SDB) and orofacial development. Questionnaires were completed about sleep, snoring, apneas, enuresis, sucking habits, and adenotonsillar surgery and, from age 12, about allergies, asthma, and general health. Children snoring regularly had an ENT- examinations including sleep studies (at ages 4 and 12) and an orthodontic evaluation. Development of biometric data in snoring children and not snoring controls was studied in relation to adenotonsillar surgery. Result: Of the original group of 615 children, 509 (83%) participated at age 6 and 393 (64%) at age 12. 27 snored regularly and 231 did not snore at age 12. Differences between groups were seen on all answers. From age 4–12 the prevalence of OSA decreased from 3.1% to 0.8%, and the minimum prevalence of snoring regularly from 5.3% to 4.2%. The odds for a child who snored regularly at four or six to be snoring regularly at age 12 was 3.7 times greater than for a not snoring child in spite of surgery (OR 3.7, 95% CI 2.4-5.7). 63 children were operated for snoring by age 12, of them 14 never snored and 17 snored regularly at age 12. Cross-bite was more common among snoring children at ages 4, 6 and 12 as was a narrower maxilla. In most cases, surgery cured the snoring temporarily, but the maxillar width was still smaller by age 12—even when nasal breathing was attained. Children snoring regularly at age 12, operated or not operated, showed long face anatomy and were oral breathers; the seven cases who were not operated and the five who were still snoring in spite of surgery, did not have reduced maxillary arch width. Conclusion: The prevalence of children snoring regularly is about the same from age four to twelve in a cohort where adenotonsillar surgery has been performed on obstructed cases, but the prevalence of OSA decreases considerably. The children snoring regularly have a more narrow maxilla compared to children not snoring—a condition that is not changed by adenotonsillar surgery regardless of symptom relief.

<p>Proper morphogenesis is essential for both form and function of mammalian craniofacial and neural tube development. Craniofacial deformities and neural tube defects are highly prevalent human birth defects. Although studies concerning craniofacial and neural tube development have revealed important genetic and/or environmental factors, understanding the mechanisms underlying proper development and the defects remain incomplete. </p><p>Among many genes that were cloned as the gastrula organizer genes in 1990s, Nog, a secreted BMP antagonist, is expressed in the relevant domains during craniofacial and neural tube development. Previous studies show that Nog null embryos exhibit fully penetrant spina bifida (open spine) and to the lesser extent exencephaly (open brain). Moreover, Nog null mice display deformities in skeletal structures including defects in craniofacial skeleton. As such, Nog is essential for proper neural tube and craniofacial development. However, it is still not clear that which domain(s) of Nog are responsible for proper craniofacial development or neural tube closure. In addition, it is also an important question when, and in what capacity Nog is necessary during development of craniofacial and neural tube.</p> / Dissertation

<p>The tumor suppressor protein p53, encoded by Tp53 gene, is a transcription factor that regulates cell cycle arrest and apoptosis following cellular stresses that compromise DNA integrity and normal cellular function. Tp53 is mutated in approximately 50% of human cancers, thereby allowing cancer cells to replicate uncontrollably. In cancers in which Tp53 is not mutated, p53 is frequently functionally inactivated through other mechanisms. For example, Mdm2, a proximal negative regulator p53 is often overexpressed in cancers in which p53 is wild-type. Mdm2 is E3 ubiquitin ligase that binds to and targets p53 for proteasomal degradation and as well as inhibits p53 transcriptional activity. Pharmacological disruption of the Mdm2-p53 interaction in cancer cells with wild-type p53 is currently being explored as a strategy to enhance p53-mediated cell death in response to conventional chemotherapeutics. Nutlin-3, an Mdm2 inhibitor, promotes cell death in cultured cells from human medulloblastoma (MB), a common cerebellar pediatric cancer, suggesting that Mdm2 is a promising target to treat this tumor type. Consistent with this idea, studies in a mouse model of MB have shown that loss of Mdm2 limits the development of preneoplastic lesion in the cerebellum. The developing nature of the cerebellum in the youngest of MB patients is a major contributing factor to the side-effects resulting from current MB therapies. Studies in adult rodents suggest that nutlin-3 is non-genotoxic in normal homeostatic tissues; however the effects of nutlin-3 have not been evaluated in developing tissues. To gain insight into the potential side effects of p53 activation on the developing cerebellum, the pharmacological effects of Mdm2 inhibition in Granule Neuron Precursor cells (GNPs) was mimicked genetically using a mouse model in which Mdm2 could be selectively deleted in postnatal GNPs. My studies revealed that deletion of Mdm2 in GNPs led to a reduction in cerebellum size but did not negatively impact gross motor coordination. These results suggest that Mdm2 inhibitors may promote the killing of MB tumor cells of pediatric patients without minimal side effects on normal cerebellum development</p> <p>In addition to cancer, p53 has an important role guarding proliferating cells during development. Activation of p53 has been implicated in the pathology of several human congenital syndromes, and mice lacking Mdm2 die in utero due to p53-mediated apoptosis. These studies highlight the need for p53 function to be tightly regulated as even modest decreases or increases in p53 function can promote cancer or disrupt normal development, respectively. During the course of my studies on Mdm2 inhibition in MB, it was serendipitously discovered that in the absence of a wild-type level of Mdm2, the phenotypic consequences of p53 activation on the developing mouse embryo were strongly influenced by the genetic background. On a 129S6/B6 F1 hybrid genetic background, mice expressing ~30% the wild-type level of Mdm2 were viable, while mice on an inbred C57BL/6 genetic background died at birth and exhibited an array of craniofacial abnormalities including coloboma, exencephaly, and cleft palate. This is the first demonstration of a role for Mdm2 in craniofacial development. The genotype-dependence, further, indicates the presence of additional genes affecting craniofacial dysmorphology. In human pleiotropic malformation syndromes, there is often clinical variability amongst individuals with an identical underlying mutation at the major effect locus. Currently, the modifier genes that influence craniofacial dysmorphology are unknown. The allelic variants encoded by the divergent genetic backgrounds that increase the penetrance and expressivity of craniofacial malformations in the Mdm2 hypomorphic mice identify the gene and protein networks governing craniofacial development. In the future, it will be important to determine the genes that are differentially expressed between mice that express low levels of Mdm2 in C57BL/6 and 129S6/B6 F1 genetic backgrounds. The results from this comparison are predicted to lead to the identification of candidate genes that influence craniofacial development through the modulation of p53 function.</p>

Clefts of the lip and/or palate (CL/P) are one of the most common birth defects in the world occurring about every 1 in 700 live births. Individuals with non-syndromic clefting (NSCL/P) account for about 70% of all cleft cases and exhibit a cleft only whereas syndromic occurrences (SCL/P) include additional cognitive or structural abnormalities. Linkage, genome-wide association, candidate gene, animal model, sequencing and copy number variant (CNV) analyses have been used to study CL/P and have established that it is a heterogeneous, complex disorder. However, the impact of identified sequence variants on protein structure and the contribution of structural genetic variation to CL/P remains poorly understood. In our first analysis we reassessed the phenotype of a 30-year-old individual of SCL/P and noticed phenotypic overlap with Hartsfield syndrome, a rare syndrome resulting from sequence variants in Fibroblast growth factor 1 (FGFR1). We sequenced the coding region of FGFR1 and identified a novel, de novo variant. Due to the fact sequence variants in FGFR1 contribute to multiple syndromes encompassing a wide phenotypic spectrum, we performed an extensive literature search to record every published sequence variant of FGFR1 and mapped it to the protein structure by disease and phenotype. Although no statistically significant protein domain-phenotype correlations were identified, many regions neared significance. This work stresses the need for systematic, comprehensive phenotyping of patients and provides a method for assessing the impact of the location of sequence variants within the 3D structure of the protein. Although rare and common CNVs have been identified in individuals with CL/P, prior to our work no large-scale studies of rare CNVs for the identification of novel clefting genes had been performed. For our second set of analyses, we conducted two such studies, first focusing on a smaller cohort of 140 individuals with NSCL/P from the Philippines to establish our informatic and functional validation pipeline. We used whole-genome tiling arrays to assess rare deletions overlapping genes not previously implicated in clefting, and identified one deletion overlapping Isthmin1 (ISM1) and a deletion just 3’ of the gene in a second affected individual. Functional validation of Ism1 in Xenopus laevis showed strong expression in structures necessary for craniofacial development, and morpholino and CRISPR/Cas9 knockdown of Ism1 resulted in a median cleft lip in some embryos, establishing ISM1 as a novel craniofacial patterning gene. We then expanded our study and assessed genomic CNVs in 1021 individuals with NSCL/P and 81 individuals with SCL/P, finding no differences in CNV number, load or burden between these groups. We also identified 8 putative clefting genes overlapped by deletions in two or more individuals but at a rare (< 1% frequency) in the cohort. Functional validation of these genes using CRISPR/Cas9 in zebrafish and Xenopus tropicalis is currently underway. This work has identified a novel sequence variant leading to the diagnosis of Hartsfield syndrome in an individual with SCL/P, developed an innovative method for assessing the impact of sequence variation on protein structure, improved our understanding of the contribution of CNVs to SCL/P and NSCL/P and identified several putative novel clefting loci which may help explain a portion of the missing heritability of CL/P.

No description available.

No description available.